Alendronate and raloxifene use related to cardiovascular diseases: Differentiation by different dosing regimens of alendronate

Clinical Therapeutics

Volumn 33, Issue 9, 2011, Pages 1173-1179

  Lu, Pei Yu ^a   Hsieh, Chi Feng ^a   Tsai, Yi Wen ^a   Huang, Weng Foung ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Acute myocardial infarction; Alendronate; Atrial fibrillation; Stroke; Women

Indexed keywords

ALENDRONIC ACID; RALOXIFENE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PRESCRIPTION; SPINE FRACTURE; STROKE; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; PROPORTIONAL HAZARDS MODELS; RALOXIFENE; RETROSPECTIVE STUDIES; RISK; TAIWAN;

EID: 80052985088     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.07.012     Document Type: Article

References (26)

1. Cecilia D., Jodar E., Fernandez C., et al. Effect of alendronate in elderly patients after low trauma hip fracture repair. Osteoporos Int 2009, 20:903-910.
2. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 1998, 280:2077-2082.
3. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
4. Stafford R.S., Drieling R.L., Hersh A.L. National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Arch Intern Med 2004, 164:1525-1530.
5. Strampel W., Emkey R., Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 2007, 30:755-763.
6. Diel I.J., Bergner R., Grotz K.A. Adverse effects of bisphosphonates: current issues. J Support Oncol 2007, 5:475-482.
7. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
8. Heckbert S.R., Li G., Cummings S.R., et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008, 168:826-831.
9. Bhuriya R., Khraisat A., Molnar J., et al. Use of bisphosphonate is associated with a higher risk of serious atrial fibrillation in postmenopausal women: a meta-analysis [Abstract 2159]. Circulation 2008, 118:S678.
10. Loke Y.K., Jeevanantham V., Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 2009, 32:219-228.
11. Miranda J., Tamariz L., Urena J., et al. A meta-analysis of the risk of atrial fibrillation in bisphosphonate users. Chest 2008, 134:s1002.
12. Cummings S.R., Schwartz A.V., Black D.M. Alendronate and atrial fibrillation. N Engl J Med 2007, 356:1895-1896.
13. Karam R., Camm J., McClung M. Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 2007, 357:712-713.
14. Bunch T.J., Anderson J.L., May H.T., et al. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 2009, 103:824-828.
15. Sorensen H.T., Christensen S., Mehnert F., et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008, 336:813-816.
16. Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates U.S. Food and Drug Administration, Accessed July 22, 2011. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm.
17. Huang W.F., Tsai Y.W., Wen Y.W., et al. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene. Menopause 2010, 17:57-63.
18. Barrett-Connor E., Mosca L., Collins P., et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006, 355:125-137.
19. Mosca L., Grady D., Barrett-Connor E., et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 2009, 40:147-155.
20. National Health Insurance Research Database Accessed July 22, 2011. http://w3.nhri.org.tw/nhird/en/index.htm.
21. Romano P.S., Roos L.L., Jollis J.G. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol 1993, 46:1075-1079.
22. Sorensen H.T., Christensen S., Mehnert F., et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008, 336:813-816.
23. Ensrud K., Genazzani A.R., Geiger M.J., et al. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol 2006, 97:520-527.
24. Barrett-Connor E., Grady D., Sashegyi A., et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (multiple outcomes of raloxifene evaluation) randomized trial. JAMA 2002, 287:847-857.
25. Licata A.A. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 2005, 39:668-677.
26. Rogers M.J., Gordon S., Benford H.L., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88:2961-2978.